Biosimilares/General

PANLAR emite declaración de consenso sobre biosimilares

Biosimilares/General | Posted 16/07/2021

PANLAR presentó su postura sobre los medicamentos biosimilares en su propio congreso en Argentina. A través de la declaración de consenso, los especialistas de PANLAR buscan demostrar la eficacia, farmacovigilancia, regulación, calidad y seguridad de los medicamentos biosimilares. 

Diferencias entre los medicamentos genéricos y los biosimilares

Biosimilares/General | Posted 16/07/2021

Medicamento biosimilar se usa para referirse a aquel medicamento biológico que ha demostrado ser altamente similar al medicamento de referencia, en cuanto a sus propiedades físicas, químicas y biológicas, habiendo esto sido demostrado por ejercicios comparativos analíticos y clínicos rigurosos. 

Biosimilar pipelines for South Korean firms: LG Chem and GC Pharma

Biosimilares/General | Posted 09/07/2021

Biosimilar makers from South Korea are making their mark, not only in South Korea, but around the world when it comes to biosimilars. Celltrion Healthcare (Celltrion) and Samsung Bioepis (Samsung and Biogen’s joint venture) are already becoming major players in the world of biosimilars. While, other Korean companies, such as LG Chem Life Sciences (LG Chem) and GC Pharma (formerly Green Cross) are also expanding their biosimilar pipelines.

US biosimilars information guides and support for cancer biosimilars

Biosimilares/General | Posted 02/07/2021

Pharmaceutical giant, Pfizer, and the Cancer Support Community, in the US, have published guides to biosimilars. In addition, Pfizer is collaborating with The National Comprehensive Cancer Network® (NCCN®) to fund projects to support innovation related to appropriate biosimilar adoption in oncology.

Biobadamérica promueve el uso de fármacos biológicos y biosimilares en Latinoamérica

Biosimilares/General | Posted 25/06/2021

La Sociedad Española de Reumatología (SER) creó en el año 2007 la plataforma Biobadamérica, un proyecto colaborativo a nivel internacional, para promover la puesta en marcha de registros nacionales de seguridad en el uso de fármacos biológicos y biosimilares en países de Latinoamérica [1]. 

El rol del paciente en los tratamientos con biosimilares en Argentina

Biosimilares/General | Posted 21/06/2021

Así es como reflexiona el Dr Eduardo Mysler, director médico de la Organización Médica de Investigación (OMI) y especialista en reumatología con una larga carrera en investigación que ‘los pacientes tienen que entender todos los detalles de su enfermedad’.

US Supreme Court rejects Enbrel patent challenge from Sandoz

Biosimilares/General | Posted 11/06/2021

The US Supreme Court has declined to review a patent challenge from Sandoz on Amgen’s blockbuster anti-inflammatory, Enbrel (etanercept). This means Sandoz will not be able to launch its etanercept biosimilar, Erelzi (etanercept-szzs), on the US market until 2029. 

Biosimilar pipelines for South Korean firms: Celltrion and Samsung Bioepis

Biosimilares/General | Posted 04/06/2021

Biosimilars are becoming more important around the world and Korean companies, such as Celltrion Healthcare (Celltrion) and Samsung Bioepis (Samsung and Biogen’s joint venture), are fast becoming major players both in Korea but also worldwide.

Dramatic price reduction of trastuzumab in Malaysia

Biosimilares/General | Posted 07/06/2019

The price of the cancer drug trastuzumab has dropped by more than half in Malaysia following a recent tender to the Ministry of Health.

Biosimilar pipelines for South Korean firms: Chong Kun Dang, DM Bio and HK inno.N

Biosimilares/General | Posted 31/05/2021

South Korea is becoming a more and more important spot on the map when it comes to biosimilars. Although Celltrion Healthcare (Celltrion) and Samsung Bioepis (Samsung and Biogen’s joint venture) are leading the way in Korea and worldwide, other Korean companies, such as Chong Kun Dang Pharmaceutical (Chong Kun Dang), DM Bio (joint venture between Dong-A ST and Meiji Holdings) and HK inno.N (previously CJ Healthcare), are also expanding their biosimilar pipelines.